Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System.
#Vray stock registration
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction. Riley Securities and BTIG acted as co-managers for the offering.
Guggenheim Securities also acted as a book-running manager for the offering. Piper Sandler and Stifel acted as the joint book-running managers for the offering.
ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses. All of the shares sold in the offering were sold by ViewRay.
#Vray stock full
(Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the closing of an additional 1,875,000 shares of common stock following the exercise in full of the underwriters' option to purchase additional shares in connection with its recently completed public offering of 12,500,000 shares of common stock, for additional gross proceeds of $10.5 million for total gross proceeds of $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. You can opt out at any time.CLEVELAND, Nov.
#Vray stock free
As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Fundamental company data provided by Zacks Investment Research. To see all exchange delays and terms of use please see disclaimer. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Our Accessibility Statement | Do Not Sell My Information does not provide financial advice and does not issue recommendations or offers to buy stock or keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price targetĬhanges. © American Consumer News, LLC dba ® 2010-2021.
0 kommentar(er)
